(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they … Continued
Every 23 minutes another woman is diagnosed with ovarian cancer. All of them have a story. This September, we’re inviting you to share your #OvarianStory. Help raise awareness of ovarian … Continued
(August 31, 2017) In answer to the persisting need for a cure to one of the deadliest diseases facing women today, Newk’s Eatery is calling on partners and patrons across … Continued
(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility … Continued
(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, … Continued
(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which … Continued
(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for … Continued
(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is … Continued
Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and … Continued
(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was … Continued
(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, … Continued
(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival … Continued
Get email updates about research news, action alerts, and ways to join the fight.
